Frontiers in Oncology (Jan 2024)
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors
Abstract
No abstracts available.Keywords
Frontiers in Oncology (Jan 2024)